# US 12,595,480 B2 · Method for producing nucleic acid molecule, biomaterial, and method for producing biomaterial > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,595,480 B2 - Document ID: US12595480B2 - Status: Granted - Kind: B2 - Application number: 17/773,461 - Filed: 2020-10-29 - Published: 2022-12-15 - Granted: 2026-04-07 - Earliest claimed: 2019-10-30 - Assignees: NEC Solution Innovators, Ltd.; Mosaic Biosciences, Inc. - Applicants: NEC Solution Innovators, Ltd.; Mosaic Biosciences, Inc. - Inventors: Tomoko Fujita; Iwao Waga; Katsunori Horii; Shintaro Kato; Martin Stanton; Andrew B. Dalby - Web page: https://patentgrep.com/patent/US12595480B2 ## CPC - C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} - C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)} - C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)} - C07K 14/71: for growth factors; for growth regulators - C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers} - C12N 15/625: {containing a sequence coding for a signal sequence} - C12N 2310/16: Aptamers - C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract The present invention provides a method for producing a nucleic acid molecule that can obtain a nucleic acid molecule that binds to a target and does not inhibit a function of the target. The production method for a nucleic acid molecule of the present invention is a method for producing a nucleic acid molecule that binds to a first biological molecule and does not inhibit a function of the first biological molecule, the method including the steps of: (A) bringing a candidate nucleic acid molecule into contact with the first biological molecule to select a nucleic acid molecule that has bound to the first biological molecule as a first selected nucleic acid molecule; and (B) selecting the first selected nucleic acid molecule as an intended nucleic acid molecule. ## Claims ### Claim 1 A nucleic acid molecule that binds to VEGF, the nucleic acid molecule comprising: any one of the following polynucleotides (a) and (b): (a) a polynucleotide that consists of a base sequence of SEQ ID NO: 1 or a partial sequence of the base sequence of SEQ ID NO: 1; and (b) a polynucleotide that consists of a base sequence having at least 80% identity to the base sequence of the polynucleotide (a), binds to VEGF, and does not inhibit a function of the VEGF. ### Claim 2 (depends on 1) The nucleic acid molecule according to claim 1, wherein the function of the VEGF is a function of binding to a VEGF receptor. ### Claim 3 (depends on 2) The nucleic acid molecule according to claim 2, wherein the function of the VEGF is a function of regulating activity of the VEGF receptor by binding to the VEGF receptor. ### Claim 4 (depends on 1) The nucleic acid molecule according to claim 1, wherein the partial sequence of the base sequence of SEQ ID NO: 1 is at least one base sequence selected from the group consisting of SEQ ID NOs: 2 to 4 and 14 to 23. ### Claim 5 (depends on 1) The nucleic acid molecule according to claim 1, wherein the polynucleotide (b) is a polynucleotide consisting of a base sequence of SEQ ID NO: 7. ### Claim 6 (depends on 1) The nucleic acid molecule according to claim 1, wherein the polynucleotide (b) is the following polynucleotide (b1): (b1) a polynucleotide that consists of a base sequence having at least 80% identity to the base sequence of the polynucleotide (a), includes a base sequence of any one of SEQ ID NOs: 2 to 4, binds to the VEGF, and does not inhibit the function of the VEGF. ### Claim 7 (depends on 1) The nucleic acid molecule according to claim 1, wherein the polynucleotide (b) is the following polynucleotide (b2): (b2) a polynucleotide that consists of a base sequence having at least 80% identity to the base sequence of the polynucleotide (a), can form a secondary structure represented by any one of the following formulae (1) to (5), the following formula (1) corresponds to SEQ ID NO: 1, the formulae (2) and (3) correspond to SEQ ID NO: 2, the formula (4) corresponds to SEQ ID NO: 3, and the formula (5) corresponds to SHO ID NO: 4, binds to the VEGF, and does not inhibit the function of the VEGF, ### Claim 8 (depends on 1) The nucleic acid molecule according to claim 1, wherein the polynucleotide (b) is the following polynucleotide (b3): (b3) a polynucleotide that consists of a base sequence having at least 80% identity to the base sequence of the polynucleotide (a), includes a base sequence of at least one of SEQ ID NOs: 5 and 6, binds to the VEGF, and does not inhibit the function of the VEGF. ### Claim 9 (depends on 1) The nucleic acid molecule according to claim 1, wherein the polynucleotide is DNA.